CLAIMS

1. ~~A method of improving female sexual function and/or treating a female sexual disorder, the method comprising applying~~Use of a topical composition ~~to a female subject's genital (arousal) area(s), wherein said topical composition~~ formulated with liposomes ~~that comprise~~comprising cannabidiol (CBD) and, optionally, one or more additional cannabinoids in the preparation of a medicament for improving female sexual function and/or treating a female sexual disorder, ~~and~~ wherein: the medicament is adapted for application to a female subject's genital (arousal) area(s); and ~~CBD-containing composition~~the medicament is adapted for ~~applied~~application to mucosal surface in ~~the~~an amount and for a period of time prior to a sexual activity ~~such that sexual function of the subject is enhanced~~for enhancement of sexual function of the subject and/or ~~the disorder is ameliorated~~for ameliorating the disorder during the sexual activity.

2. The ~~method~~use of claim 1, wherein the genital area includes genitalia with absorptive mucosa, comprising one or more of: ~~the~~ introitus, ~~the~~ vulva, ~~the~~ labia minora, ~~the~~ clitoris and ~~the~~ vaginal vault.

3. The ~~method~~use of claim 1, wherein the enhancement of ~~the~~ sexual function and/or the ameliorating~~amelioration of~~ the disorder is exhibited by one or both of the following parameters:

i. vaginal and clitoral smooth muscle relaxation; and

ii. increased vaginal and clitoral blood flow.

4. The ~~method~~use of claim 1, wherein the enhancement of ~~the~~ sexual function and/or the ameliorating~~amelioration of~~ the disorder is exhibited by one or more of the following subjectively self-reported outcomes including:

i. “increased lubrication/wetness during sexual activity”;

ii. “reaching orgasm more often”;

iii. “greater ease or achieving orgasm”;

iv. “being more satisfied”;

v. “higher level of sexual desire”; and

vi. “reduction in pain during sexual activity”.

5. The ~~method~~use of claim 1, wherein the subject is premenopausal.

6. The ~~method~~use of claim ~~3 or~~ 4, wherein the outcomes ~~are~~ reported by post-menopausal women are similar to those reported by premenopausal women with respect to one or more of the following ~~parameters~~:

i. improved arousal;

ii. improved lubrication; and

iii. improved ease of achieving orgasm.

7. The ~~method~~use of claim 1, wherein the total amount of CBD ~~applied~~comprised in the topical composition is from 5 mg to 1,000 mg of CBD; ~~, preferably~~ 10-100 mg of CBD; or ~~, more preferably,~~ 20-40 mg of CBD.

8. The ~~method~~use of claim 1, wherein the ~~CBD-containing composition is applied at~~period of time is 5-30 mins prior to the sexual activity.

9. The ~~method~~use of claim 1, where the additional cannabinoid(s) is/are selected from the group consisting of Δ^9-THC, Δ^8-THC, CBD, and CBN.

10. The ~~method~~use of any of the preceding claims, where ~~is~~ CBD is hemp-derived and/or contain less 0.3% THC by weight.

11. The ~~method~~use of claim 1, wherein the ~~CBD-containing~~topical composition is provided in a single-use container.

12. The ~~method~~use of claim 1, wherein the ~~CBD-containing~~topical composition further comprises preservative(s) and is provided in a multi-use container.

13. The ~~method~~use of claim 1, wherein the ~~CBD-containing~~topical composition is compatible with latex and polyisoprene condoms.

14. The ~~method~~use of claim 1, wherein the ~~CBD-containing composition is provided by means of~~medicament is pre-coated on a condom ~~pre-coated with the composition~~.

15. The ~~method~~use of claim 1, wherein the concentration of CBD comprised in the topical composition is from 1 mg/ml to 40 mg/ml~~,~~; ~~preferably,~~ 5 mg/ml to 20 mg/ml; ~~more preferably,~~ or 10 mg/ml.

16. The ~~method~~use of claim 1, wherein ~~CBD-containing~~the topical composition comprises liposomes that comprise HSPC, ascorbic acid, sodium ascorbate, propylene glycol, polyacrylate crosspolymer-6, and water or aqueous buffer, and wherein the liposomes are provided in a homogeneous suspension.

17. The ~~method~~use of claim 1, wherein the ~~composition is applied~~period of time is 1-60 min; ~~prior to sexual activity, preferably,~~ 5-40 min; ~~more preferably~~ or 15-20 min.

18. The ~~method~~use of claim 1, wherein the subject is afflicted with a disorder selected from: (1) Sexual Interest/Arousal Disorder (SIAD); and (2) Female Orgasmic Disorder.

~~19. The method of claim 18, wherein the subject, upon having been treated with the CBD-containing composition for 3-6 months, reports arousal and or orgasmic improvements as measured by FSFI.~~

~~21. The method of claim 18, wherein the improvement in sexual interest/arousal domain is by 1.5-2 points, and by 1.5-2 points in the orgasm domain of the FSFI.~~

~~23. The method of claim 1, wherein the off-set time following the application of the CBD-containing composition is 0.5-5 hrs, preferably, 1-3 hrs, more preferably 1-2 hrs.~~

~~25.~~19. The ~~method~~use of claim 1, wherein ~~CBD-containing~~the topical composition further comprises a phosphodiesterase type 5 inhibitor.

~~26.~~20. The ~~method~~use of claim 19, wherein the inhibitor is chosen from sildenafil, tadalafil, vardenafil, and udenafil.

~~27.~~21. The ~~method~~use of claim 1, wherein ~~CBD-containing~~the topical composition further comprises another direct smooth muscle relaxant.

~~28.~~22. The ~~method~~use of claim ~~24~~21, wherein the relaxant is chosen from prostaglandin E1, papaverine, and minoxidil.

~~29.~~23. The ~~method~~use of claim 1, wherein ~~CBD-containing~~the topical composition further comprises an alpha-blocker.

~~30.~~24. The ~~method~~use of claim ~~1~~23, wherein the alpha-blocker is phentolamine.

~~31.~~25. The ~~method~~use of claim 1, wherein ~~CBD-containing~~the topical composition further comprises flibanserin~~ thereby augmenting sexual desire~~.

~~32.~~26. The ~~method~~use of claim 1, wherein ~~CBD-containing~~the topical composition further comprises bremelanotide~~ thereby augmenting sexual desire~~.